Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Bifurcation Lesion Treatment Option: Insights From Clinical Literature | James Hermiller, M.D.

1,753 views

Published on

TCT2015 Presentation - James Hermiller, M.D.

Published in: Health & Medicine
  • Be the first to comment

Bifurcation Lesion Treatment Option: Insights From Clinical Literature | James Hermiller, M.D.

  1. 1. J Hermiller MD 1 Bifurcation Lesion Treatment Option: Insights From Clinical Literature James Hermiller, MD, FACC, FSCAI St Vincent Medical Group St Vincent Heart Center of Indiana Indianapolis, IN Presentation Theater: Tryton Pivotal: Randomized Trial and Confirmatory Study – Implications for Everyday Practice Tuesday, October 13, 2015 11:53 AM - 12:02 PM Room: Moscone South, Exhibit Hall, Presentation Theater 4 Presentation Theater Programs
  2. 2. J Hermiller MD 2 Disclosure Statement of Financial Interest • Grant/Research Support • Consulting Fees/Honoraria • Edwards, Medtronic, Abbott, St Jude, BSC • Edwards, Medtronic, Abbott, St Jude, BSC Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial Relationship Company
  3. 3. J Hermiller MD 3 Key Points • Bifurcation Lesions: Continues to be a problem – we don’t have the right tools
  4. 4. J Hermiller MD 4 Key Points • Bifurcation Lesions: Continues to be problem Only Lesion Subset Not Routinely Stented • Combined Literature: Supports Provisional over 2 Stent Strategies • Study Population Primarily Focused on Small SB – BBC 1 – Nordic 1 • Studies with Large SB Favors 2 Stent Approach – DK Crush – 2 Stent ‘Simple’ Dedicated Stent • Dedicated Side Branch Stent: Focused on Providing Straight Forward 2 stent solution
  5. 5. J Hermiller MD 5 Bifurcation Lesions are Common “All Comers” Studies % Patients % Lesions Leaders Trial1,2 29.1% 21.6% Nobori 23 17.5% 16.9% xSearch4 22.2% N/A Average 22.9% 19.3% 1. Windecker et al. Lancet 2008; 372: 1163–73 2. Wykrzykowska, EuroPCR ’09 3. Danzi, EuroPCR ‘09 4. Serruys, ACC ‘08
  6. 6. J Hermiller MD 6 Bifurcation Lesions Yield Complications • Thrombosis Rate – Incidence: 3.6-3.9% – Hazard Ratio: 4.6-6.5 • Restenosis Rates – Angiographic 20-40%
  7. 7. J Hermiller MD 7 Bifurcation Lesions: Large Variation: Disease, Angle & Diameter Case Courtesy of Drs Kutcher & Holland, USA Courtesy of P Brunel, France Courtesy of Dr. Dumonteil, France Courtesy of Prof. R. Kornowski, Israel Courtesy of Dr. Th. Lefèvre, France Courtesy of Dr. Schulze, Germany Courtesy of Dr. M. Lesiak, Poland Courtesy of Drs. E. Grübe - R. Müller, Germany
  8. 8. J Hermiller MD 8 Multiple Treatment Strategies Implementation: High Variability/Poorly Characterized
  9. 9. J Hermiller MD 9
  10. 10. J Hermiller MD 10 Forest plots from the included trials. Odds ratios of target vessel revascularization (A), and main vessel restenosis (B) in the large side branch subgroup (patients with side branch diameter ≥2.5 mm) SB <2.5 mm: 1-stent SB ≥2.5 mm: 2-stent
  11. 11. J Hermiller MD 11 Studies Involving Large Side Branches Favor 2- stent Strategy
  12. 12. J Hermiller MD 12 Tryton: Dedicated 2 Stent Approach Baseline Tryton Final
  13. 13. J Hermiller MD 13 Key Points • Bifurcation Lesions: Continues to be problem Only Lesion Subset Not Routinely Stented • Combined Literature: Supports Provisional over 2 Stent Strategies • Study Population Primarily Focused on Small SB – BBC 1 – Nordic 1 • Studies with Large SB Favors 2 Stent Approach – DK Crush – 2 Stent ‘Simple’ Dedicated Stent • Dedicated Side Branch Stent: Focused on Providing Straight Forward 2 stent solution
  14. 14. J Hermiller MD 14 Thank You!!!!!! Herms2@gmail.com

×